Table 2. Leukemia-specific SIRs among... | American Society of Hematology

Table 2.

Leukemia-specific SIRs among patients with SCD, California, 1988-2014

	Observed cases	Expected cases	SIR	95% CI
Leukemia	12	5.17	2.32	(1.20-4.05)
Sex
Male	5	2.71	1.85	(0.60-4.31)
Female	7	2.47	2.84	(1.14-5.84)
Age at diagnosis, y
Pediatric, <15	1	1.47	0.68	(0.02-3.79)
AYA, 15-39	6	1.78	3.37	(1.24-7.33)
Adult, ≥40	5	1.92	2.60	(0.84-6.07)
SCD severity*
Less severe	4	2.59	1.54	(0.42-3.95)
Severe	8	1.81	4.41	(1.91-8.70)
Treatment era†
1988-1999	5	1.92	2.61	(0.85-6.08)
2000-2014	7	3.26	2.15	(0.86-4.43)

	Observed cases	Expected cases	SIR	95% CI
Leukemia	12	5.17	2.32	(1.20-4.05)
Sex
Male	5	2.71	1.85	(0.60-4.31)
Female	7	2.47	2.84	(1.14-5.84)
Age at diagnosis, y
Pediatric, <15	1	1.47	0.68	(0.02-3.79)
AYA, 15-39	6	1.78	3.37	(1.24-7.33)
Adult, ≥40	5	1.92	2.60	(0.84-6.07)
SCD severity*
Less severe	4	2.59	1.54	(0.42-3.95)
Severe	8	1.81	4.41	(1.91-8.70)
Treatment era†
1988-1999	5	1.92	2.61	(0.85-6.08)
2000-2014	7	3.26	2.15	(0.86-4.43)

AYA, adolescent and young adult.

Patients with an average of ≥3 visits per year were defined as severe SCD; patients with an average <3 visits per year were defined as less severe SCD.¹⁷

†

Hydroxyurea was approved by the FDA in February 1998.

View Large

This Feature Is Available To Subscribers Only